

Supplementary Table 1. Main effect of body composition measurements for risk of any colorectal neoplasia and high-risk adenoma among men in the Aspirin/Folate Polyp Prevention Study.

Baseline measurement	Colorectal neoplasia			HRA	
	Total	No. with endpoint (%)	RR ^a (95% CI)	No. with endpoint (%)	RR ^a (95% CI)
Height, m					
<1.70	82	40 (49)	1 (Ref)	12 (15)	1 (Ref)
1.70-1.79	304	132 (43)	0.88 (0.68, 1.15)	45 (15)	0.93 (0.52, 1.67)
≥1.80	302	147 (49)	1.04 (0.81, 1.36)	50 (17)	1.25 (0.71, 2.21)
Weight, kg					
<80	219	98 (45)	1 (Ref)	37 (17)	1 (Ref)
80-89	231	111 (48)	1.01 (0.83, 1.23)	32 (14)	0.86 (0.56, 1.32)
≥90	240	111 (46)	1.03 (0.84, 1.27)	38 (16)	1.04 (0.69, 1.56)
BMI, kg/m ²					
<25	166	71 (43)	1 (Ref)	22 (13)	1 (Ref)
25-29	371	174 (47)	1.06 (0.86, 1.30)	59 (16)	1.14 (0.73, 1.77)
≥30	151	74 (49)	1.13 (0.89, 1.44)	26 (17)	1.36 (0.80, 2.29)
BSA ^b , m ²					
<2.00	285	120 (42)	1 (Ref)	41 (14)	1 (Ref)
2.00-2.09	172	91 (53)	1.20 (0.98, 1.47)	31 (18)	1.34 (0.88, 2.06)
≥2.10	231	108 (47)	1.14 (0.94, 1.39)	35 (15)	1.23 (0.81, 1.87)
FFM ^c , kg					
<60	193	87 (45)	1 (Ref)	30 (16)	1 (Ref)
60-64	229	105 (46)	0.98 (0.79, 1.21)	38 (17)	1.14 (0.74, 1.76)
≥65	266	127 (48)	1.08 (0.87, 1.33)	39 (15)	1.11 (0.72, 1.72)
FM ^d , kg					
<20	261	117 (45)	1 (Ref)	38 (15)	1 (Ref)
20-24	193	92 (48)	0.98 (0.80, 1.20)	31 (16)	1.00 (0.65, 1.53)
≥25	234	110 (47)	1.03 (0.85, 1.25)	38 (16)	1.17 (0.78, 1.76)

Abbreviations: BSA, body surface area; BMI, body mass index; CI, confidence interval; FFM, fat-free mass; FM, fat mass; HRA, high-risk adenoma; RR, risk ratio.

Note: Two men were missing height, and thus excluded from the calculations of BMI, BSA, FFM, and FM.

^a RR adjusted for age, clinical center, aspirin assignment, and folic acid assignment. Endpoints were contrasted to those without colorectal neoplasia.

^b Calculated using the method of DuBois and DuBois (5).

^c Calculated using the method of Janmahasatian et al. (6).

^d Weight minus FFM.

Supplementary Table 2. Main effect of body composition measurements for risk of any colorectal neoplasia and high-risk adenoma among women in the Aspirin/Folate Polyp Prevention Study.

Baseline measurement	Total	Colorectal neoplasia		HRA	
		No. with endpoint (%)	RR ^a (95% CI)	No. with endpoint (%)	RR ^a (95% CI)
Height, m					
<1.60	100	37 (37)	1 (Ref)	9 (9)	1 (Ref)
1.60-1.69	225	84 (37)	1.11 (0.82, 1.51)	20 (9)	1.05 (0.49, 2.24)
≥1.70	69	29 (42)	1.13 (0.74, 1.72)	4 (6)	0.69 (0.21, 2.26)
Weight, kg					
<70	209	73 (35)	1 (Ref)	17 (8)	1 (Ref)
70-79	88	28 (32)	0.90 (0.63, 1.30)	5 (6)	0.71 (0.28, 1.82)
≥80	97	49 (51)	1.38 (1.04, 1.83)	11 (11)	1.40 (0.70, 2.82)
BMI, kg/m ²					
<25	167	53 (32)	1 (Ref)	10 (6)	1 (Ref)
25-29	136	55 (40)	1.22 (0.89, 1.66)	15 (11)	2.01 (0.94, 4.29)
≥30	91	42 (46)	1.35 (0.98, 1.85)	8 (9)	1.40 (0.57, 3.47)
BSA ^b , m ²					
<1.70	155	56 (36)	1 (Ref)	14 (9)	1 (Ref)
1.70-1.79	87	28 (32)	0.98 (0.68, 1.41)	4 (5)	0.55 (0.17, 1.74)
≥1.80	152	266 (43)	1.17 (0.88, 1.57)	15 (10)	1.09 (0.56, 2.14)
FFM ^c , kg					
<40	119	42 (35)	1 (Ref)	8 (7)	1 (Ref)
40-44	150	50 (33)	0.99 (0.71, 1.38)	13 (9)	1.35 (0.57, 3.19)
≥45	125	58 (46)	1.25 (0.91, 1.72)	12 (10)	1.39 (0.58, 3.13)
FM ^d , kg					
<30	249	85 (34)	1 (Ref)	19 (8)	1 (Ref)
30-34	64	25 (39)	1.18 (0.82, 1.70)	7 (11)	1.59 (0.68, 3.71)
≥35	81	40 (49)	1.36 (1.01, 1.81)	7 (9)	1.15 (0.51, 2.55)

Abbreviations: BSA, body surface area; BMI, body mass index; CI, confidence interval; FFM, fat-free mass; FM, fat mass; HRA, high-risk adenoma; RR, risk ratio.

^a RR adjusted for age, clinical center, aspirin assignment, and folic acid assignment. Endpoints were contrasted to those without colorectal neoplasia.

^b Calculated using the method of DuBois and DuBois (5).

^c Calculated using the method of Janmahasatian et al. (6).

^d Weight minus FFM.

Supplementary Table 3. Aspirin treatment effect for risk of any colorectal neoplasia and high-risk adenoma according to body composition measurements among men in the Aspirin/Folate Polyp Prevention Study.

Baseline measurement	Colorectal neoplasia		HRA	
	81 mg/d aspirin vs placebo RR ^a (95% CI)	325 mg/d aspirin vs placebo RR ^a (95% CI)	81 mg/d aspirin vs placebo RR ^a (95% CI)	325 mg/d aspirin vs placebo RR ^a (95% CI)
Height, m				
<1.70	0.60 (0.28, 1.24)	1.39 (0.85, 2.28)	0.68 (0.18, 2.63)	1.73 (0.53, 5.60)
1.70-1.79	0.89 (0.63, 1.26)	1.09 (0.80, 1.49)	0.55 (0.24, 1.24)	1.12 (0.60, 2.09)
≥1.80	0.72 (0.55, 0.95)	0.83 (0.63, 1.08)	0.54 (0.30, 0.99)	0.75 (0.43, 1.32)
P-interaction	0.52	0.15	0.95	0.39
Weight, kg				
<80	0.77 (0.51, 1.15)	1.22 (0.87, 1.71)	0.48 (0.20, 1.16)	1.37 (0.74, 2.53)
80-89	0.88 (0.62, 1.23)	0.94 (0.69, 1.29)	0.91 (0.40, 2.07)	1.08 (0.50, 2.34)
≥90	0.69 (0.49, 0.97)	0.84 (0.61, 1.15)	0.45 (0.22, 0.93)	0.65 (0.33, 1.28)
P-interaction	0.61	0.27	0.40	0.27
BMI, kg/m ²				
<25	0.82 (0.52, 1.28)	0.99 (0.67, 1.48)	0.72 (0.26, 1.99)	1.18 (0.51, 2.76)
25-29	0.82 (0.62, 1.08)	0.97 (0.75, 1.25)	0.63 (0.34, 1.19)	1.11 (0.65, 1.91)
≥30	0.58 (0.37, 0.92)	0.95 (0.67, 1.35)	0.36 (0.15, 0.86)	0.56 (0.25, 1.28)
P-interaction	0.43	0.99	0.51	0.35
BSA ^b , m ²				
<2.00	0.83 (0.57, 1.22)	1.30 (0.94, 1.79)	0.59 (0.25, 1.41)	1.65 (0.86, 3.14)
2.00-2.09	0.80 (0.57, 1.13)	0.82 (0.59, 1.14)	0.77 (0.35, 1.69)	0.87 (0.42, 1.81)
≥2.10	0.66 (0.47, 0.94)	0.82 (0.59, 1.12)	0.40 (0.19, 0.84)	0.51 (0.24, 1.08)
P-interaction	0.63	0.08	0.49	0.06
FFM ^c , kg				
<60	0.87 (0.56, 1.34)	1.28 (0.88, 1.86)	0.64 (0.23, 1.80)	1.86 (0.87, 3.96)
60-64	0.81 (0.56, 1.18)	1.02 (0.74, 1.41)	0.73 (0.35, 1.55)	1.09 (0.56, 2.13)
≥65	0.68 (0.50, 0.92)	0.79 (0.59, 1.06)	0.41 (0.21, 0.83)	0.49 (0.24, 1.00)
P-interaction	0.59	0.13	0.53	0.04
FM ^d , kg				
<20	0.83 (0.59, 1.18)	1.04 (0.76, 1.42)	0.58 (0.24, 1.36)	1.39 (0.74, 2.61)
20-24	0.82 (0.56, 1.20)	0.96 (0.68, 1.37)	0.68 (0.30, 1.51)	0.75 (0.34, 1.64)
≥25	0.65 (0.46, 0.93)	0.92 (0.67, 1.24)	0.48 (0.23, 0.98)	0.78 (0.40, 1.51)
P-interaction	0.57	0.84	0.81	0.35

Abbreviations: BSA, body surface area; BMI, body mass index; CI, confidence interval; FFM, fat-free mass; FM, fat mass; HRA, high-risk adenoma; RR, risk ratio.

Note: Two men were missing height, and thus excluded from the calculations of BMI, BSA, FFM, and FM.

^a RR from interaction between body composition measurement and aspirin assignment, adjusted for age, clinical center, and folic acid assignment. Endpoints were contrasted to those without colorectal neoplasia.

^b Calculated using the method of DuBois and DuBois (5).

^c Calculated using the method of Janmahasatian et al. (6).

^d Weight minus FFM.

Supplementary Table 4. Aspirin treatment effect for risk of any colorectal neoplasia and high-risk adenoma according to body composition measurements among women in the Aspirin/Folate Polyp Prevention Study.

Baseline measurement	Colorectal neoplasia		HRA	
	81 mg/d aspirin vs placebo RR ^a (95% CI)	325 mg/d aspirin vs placebo RR ^a (95% CI)	81 mg/d aspirin vs placebo RR ^a (95% CI)	325 mg/d aspirin vs placebo RR ^a (95% CI)
Height, m				
<1.60	0.77 (0.40, 1.49)	0.87 (0.47, 1.60)	—	—
1.60-1.69	0.71 (0.46, 1.09)	0.91 (0.62, 1.34)	—	—
≥1.70	1.98 (0.77, 5.11)	1.47 (0.56, 3.87)	—	—
P-interaction	0.15	0.63	—	—
Weight, kg				
<70	0.86 (0.54, 1.37)	0.89 (0.57, 1.41)	0.61 (0.18, 2.03)	0.76 (0.25, 2.36)
70-79	1.07 (0.50, 2.31)	1.01 (0.46, 2.19)	0.43 (0.05, 3.92)	0.55 (0.07, 4.71)
≥80	0.77 (0.44, 1.37)	1.00 (0.62, 1.60)	0.18 (0.02, 1.35)	0.32 (0.07, 1.45)
P-interaction	0.80	0.94	0.60	0.67
BMI, kg/m ²				
<25	0.77 (0.44, 1.38)	1.06 (0.63, 1.76)	0.86 (0.18, 4.10)	1.05 (0.23, 4.83)
25-29	0.89 (0.53, 1.51)	0.87 (0.51, 1.48)	0.27 (0.06, 1.15)	0.65 (0.21, 2.00)
≥30	1.01 (0.58, 1.76)	0.93 (0.55, 1.55)	0.34 (0.05, 2.38)	0.20 (0.02, 1.56)
P-interaction	0.81	0.87	0.53	0.44
BSA ^b , m ²				
<1.70	0.75 (0.44, 1.29)	0.91 (0.56, 1.49)	—	—
1.70-1.79	0.86 (0.39, 1.92)	0.93 (0.43, 2.02)	—	—
≥1.80	1.01 (0.63, 1.61)	1.01 (0.63, 1.62)	—	—
P-interaction	0.72	0.77	—	—
FFM ^c , kg				
<40	0.94 (0.50, 1.77)	1.09 (0.61, 1.93)	—	—
40-44	0.74 (0.43, 1.28)	0.80 (0.45, 1.41)	—	—
≥45	1.00 (0.59, 1.67)	1.00 (0.61, 1.62)	—	—
P-interaction	0.73	0.74	—	—
FM ^d , kg				
<30	0.86 (0.55, 1.33)	0.94 (0.62, 1.44)	—	—
30-34	1.20 (0.56, 2.57)	1.34 (0.64, 2.81)	—	—
≥35	0.74 (0.41, 1.33)	0.79 (0.46, 1.37)	—	—
P-interaction	0.61	0.54	—	—

Abbreviations: BSA, body surface area; BMI, body mass index; CI, confidence interval; FFM, fat-free mass; FM, fat mass; HRA, high-risk adenoma; RR, risk ratio.

Note: Results not reported when the endpoint occurred in fewer than 5 participants for a level of the body composition variable or were not estimable by aspirin dose.

^a RR from interaction between body composition measurement and aspirin assignment, adjusted for age, clinical center, and folic acid assignment. Endpoints were contrasted to those without colorectal neoplasia.

^b Calculated using the method of DuBois and DuBois (5).

^c Calculated using the method of Janmahasatian et al. (6).

^d Weight minus FFM.